Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 8;9(4):e1144.
doi: 10.7759/cureus.1144.

Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue

Zoltan Varga  1 , Syed Rafay Ali Sabzwari  1 , Veronika Vargova  2
Affiliations
Review

Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue

Zoltan Varga et al. Cureus. .

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are drugs with analgesic, anti-inflammatory, and antipyretic activity. Their effect is achieved by the reduction in synthesis of prostanoids. Inhibition of prostanoids is responsible for a substantial risk of adverse effects. The risk of side effects affecting the gastrointestinal tract and kidneys has long been known. The possibilities of blood pressure elevation and the development of congestive heart failure are also widely recognized. Increased incidence of acute myocardial infarction in clinical trials with rofecoxib drew attention to the potential cardiotoxicity of selective cyclooxygenase-2 inhibitors, and similarly, concerns have been raised regarding the cardiovascular safety of non-selective NSAIDs. The safety of NSAIDs with regards to cardiovascular events has been studied in recent years in a large number of retrospective and prospective clinical studies and meta-analyses. The results indicate that cardiotoxicity is a class effect, but the magnitude of the risk is widely variable between individual NSAID drugs. This article aims to summarize the available data on the risk of adverse cardiovascular events with NSAIDs, the clinical impact of these events and possible underlying mechanisms.

Keywords: adverse effect; arterial hypertension; cardiovascular event; cardiovascular risk; heart failure; non-steroidal anti-inflammatory drugs.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. McGettigan P, Henry D. PLoS Med. 2013;10:1001388. - PMC - PubMed
    1. Recent advances in medical diagnosis and treatment. Douthwaite AH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2086550/pdf/brmedj04278-000.... BMJ. 1938;1:1143–1146. - PMC - PubMed
    1. Acute oliguric renal failure induced by indomethacin: possible mechanism. Walshe JJ, Venuto RC. Ann Intern Med. 1979;91:47–49. - PubMed
    1. Effects of prostaglandin synthesis inhibition on blood pressure and humoral factors in exercising, sodium-deplete normal man. Staessen J, Fagard R, Lijnen P, et al. http://journals.lww.com/jhypertension/Abstract/1983/08000/Effects_of_Pro.... J Hypertens. 1983;1:123–130. - PubMed
    1. Prostaglandins in congestive heart failure and the effects of nonsteroidal anti-inflammatory drugs. Cannon PJ. Am J Med. 1986;81:123–132. - PubMed